Abstract
Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5%) completed the induction cycle and 215 (52.3%) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1%) and 60 (14.6%) patients. Ninetythree patients (30.2%) stopped BCG, 9 (9.7%) for recurrence and 14 (15.1%) for grade-3 toxicity. Intriguingly, 55 (59.1%) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60% of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.
| Original language | English |
|---|---|
| Pages (from-to) | 20-24 |
| Number of pages | 5 |
| Journal | Urologia Internationalis |
| Volume | 96 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2016 |
Fingerprint
Keywords
- Bacillus Calmette Guèrin
- Compliance
- Immunotherapy
- Intravesical instillation
- Non-muscle invasive bladder cancer
- Toxicity
ASJC Scopus subject areas
- Urology
Cite this
Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? / Serretta, Vincenzo; Gesolfo, Cristina Scalici; Alonge, Vincenza; Cicero, Giuseppe; Moschini, Marco; Colombo, Renzo.
In: Urologia Internationalis, Vol. 96, No. 1, 01.01.2016, p. 20-24.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?
AU - Serretta, Vincenzo
AU - Gesolfo, Cristina Scalici
AU - Alonge, Vincenza
AU - Cicero, Giuseppe
AU - Moschini, Marco
AU - Colombo, Renzo
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5%) completed the induction cycle and 215 (52.3%) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1%) and 60 (14.6%) patients. Ninetythree patients (30.2%) stopped BCG, 9 (9.7%) for recurrence and 14 (15.1%) for grade-3 toxicity. Intriguingly, 55 (59.1%) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60% of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.
AB - Introduction: The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. Materials and Methods: Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. Results: A total of 411 patients were enrolled in the study. Out of these total number of patients, 380 (92.5%) completed the induction cycle and 215 (52.3%) completed one year. Toxicity requiring interruption or postponement was recorded in 25 (6.1%) and 60 (14.6%) patients. Ninetythree patients (30.2%) stopped BCG, 9 (9.7%) for recurrence and 14 (15.1%) for grade-3 toxicity. Intriguingly, 55 (59.1%) patients refused BCG due to mild discomfort and deterioration in quality of social life. Conclusions: Grades 2-3 toxicity causes BCG interruption in a few cases. Almost 60% of interruptions are attributable to persistent grade-1 toxicity, which is inadequately treated.
KW - Bacillus Calmette Guèrin
KW - Compliance
KW - Immunotherapy
KW - Intravesical instillation
KW - Non-muscle invasive bladder cancer
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=84956839074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956839074&partnerID=8YFLogxK
U2 - 10.1159/000430501
DO - 10.1159/000430501
M3 - Article
AN - SCOPUS:84956839074
VL - 96
SP - 20
EP - 24
JO - Urologia Internationalis
JF - Urologia Internationalis
SN - 0042-1138
IS - 1
ER -